melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Cobalt (Co) is a rare, essential trace element needed by adults at the level of 0.1 μg per day as part of vitamin B12. Levels above 10 mg per day can cause severe cardiomyopathies. Copper (Cu) is essential for human health and copper toxicity is rare and occurs primarily in inherited diseases of the liver. Iron (Fe) is required for hemoglobin in red blood cells. Large excesses of iron from dietary supplements, on the order of 0.5 g, can cause acute iron poisoning. Magnesium (Mg), important for many types of reactions in cells, rarely poses a hazard unless ingested by people with severe renal failure or as metal fume fever from magnesium oxide. Manganese (Mn) inhalation during mining causes manganese poisoning. Molybdenum (Mo) is an essential element with low toxicity. Its toxicity resembles copper deficiency and treatment with copper reduces the toxic effects of molybdenum. Selenium (Se) is a required nutrient to form selenoproteins; inadequate amounts lead to Keshan disease. Excess selenium causes Selenosis. However the element itself has low solubility and the biologically active forms are ions +6, +4, and +2. Zinc (Zn) has a Recommended dietary allowance of 15 mg and is only toxic at ten times that amount. Zinc toxicity is rare. Free zinc ion in solution is highly toxic to bacteria, plants, invertebrates, and fish. Metal fume fever occurs when zinc oxide (ZnO) is inhaled by welders working on galvanized steel or brass. Dietary deficits of some metals, including calcium (Ca), zinc, iron, selenium, copper, chromium and manganese increase toxic effects of metals.
No specifics on the captured were given; Agence France-Presse stated that "Venezuela regularly claims to have arrested US-backed mercenaries working to destabilize Maduro's administration." Government officials announced in late October that surveillance cameras would be deployed at a large scale, and VenApp, an application used during the 2024 Venezuelan political crisis to enable citizens to report on each other's activities, would be reactivated to allow reporting to authorities of "everything they see and everything they hear, 24 hours a day". Venezuelan opposition leader María Corina Machado said the deployment encouraged "tens and tens of thousands" of Venezuelans to join an underground movement aiming to overthrow Maduro. Machado said that the 2024 Venezuelan presidential election gave a mandate for regime change, though she said that regime change was the responsibility of Venezuelans rather than of the US.
== Mirror-image phage display == Phage display is a technique to screen large libraries of peptides for binding to a target protein. In phage display, the DNA sequence that codes the potential drug-peptide is fused to the gene of the protein coat of bacteriophages and introduced into a vector. Diversity can be introduced to the peptide by mutagenesis. The protein coats peptides are then expressed and purified, and applied to a surface of immobilized protein targets. The surface is then washed away to remove non-binding peptides, while the remaining binding peptides are eluted. Mirror-image phage display is a similar method that can be used to screen large libraries of D-peptides that bind to target L-proteins. More precisely, since D-peptides can not be expressed in bacteriophages, mirror-image phage display screens L-peptides that bind to immobilized D-proteins that are previously chemically synthesized. Because of the mirror properties of D-peptides, the D-enantiomer of an L-peptide that binds to a D-protein will bind to the L-protein. Mirror-image phage display, however, has two disadvantages when compared to phage display. Target D-proteins must be chemically synthesized, which is normally an expensive and time-consuming process. Also, the target protein must not require a cofactor or a chaperone to fold, otherwise the chemically synthesized D-protein will not fold to the target, mirror structure.
=== Other elements === Not all elements which are found in the human body in trace quantities play a role in life. Some of these elements are thought to be simple common contaminants without function (examples: caesium, titanium), while many others are thought to be active toxins, depending on amount (cadmium, mercury, lead, radioactives). In humans, arsenic is toxic, and its levels in foods and dietary supplements are closely monitored to reduce or eliminate its intake. Some elements (silicon, boron, nickel, vanadium) are probably needed by mammals also, but in far smaller doses. Bromine is used by some (though not all) bacteria, fungi, diatoms, and seaweeds, and opportunistically in eosinophils in humans. One study has indicated bromine to be necessary to collagen IV synthesis in humans. Fluorine is used by a number of plants to manufacture toxins but in humans its only known function is as a local topical hardening agent in tooth enamel.
Sources: en.wikipedia.org
Coming from a hardcore punk background and having grown up listening to Bad Brains, Cro-Mags and Leeway, they gradually became interested in the slower sound of the 1990s scene, especially that of Brooklyn, which was "very doomy, very Black Sabbath inspired", with Life Of Agony and Type O Negative. They appreciated the approach of Saint Vitus' members, who had themselves been influenced by Black Flag. They also appreciated the similar trajectory of Type O Negative, with Thépegnier particularly liking the way Carnivore—Peter Steele's previous band—sounded on the album Retaliation. Emerging from Es La Guerilla, the group of musicians who would form Hangman's Chair naturally gravitated towards a "really slow, sung, obscure" style of music. The members of Hangman's Chair cited Crowbar's Odd Fellows Rest as an early influence. The band were influenced by Type O Negative. Kerrang! noted "a much more urban, gritty feel and atmosphere" in the band's music compared to what this type of "dark metal" generally presents. Thépegnier responded that the "urban mood and cold atmosphere" reflected in their music stems from their Parisian lifestyle. Daily events in Paris have influenced Hangman's Chair, and the city has also been a source of inspiration for them. He cited Type O Negative's style as inspiring, describing their music as "urban cold wave hardcore" that blended their Brooklyn urban ambience with "dark" gothic metal, a combination he said was mainly apparent in their lyrics and album covers.
=== Peru === The travelers gradually descended into the cinchona forests and former Inca territories. In Riobamba, they stayed with Montufar’s brother, where Humboldt accessed rare sixteenth-century manuscripts written in an extinct dialect and later translated into Spanish. These documents described pre-conquest events and the major eruption of Nevado de Altar volcano, which affected nearby towns with ash for seven years. Traveling from Riobamba to Cuenca across the Paramo of Azuay, Humboldt studied the remains of the Inca road, notable for its precise porphyry paving and straightness, comparable to Roman roads, leading to Cuzco. He also visited the ruins of Inca Tapayupangi’s palace and its summer house carved from rock, which offered impressive views and prompted Humboldt to admire Inca public works. Southward, the group had to ford the Rio Guancabamba, a tributary of the Amazon, twenty-seven times. Although not wide, the river’s strong current endangered their mules, which carried important collections. Humboldt described the anxiety of watching their passage. Further along, he observed the local postal system known as “el correo que nada,” where a messenger swam downstream with mail secured in a cotton handkerchief, sometimes using a balsa log to rest and stopping at huts for food and shelter. Humboldt confirmed the reliability of this system, having received mail sent this way in Paris, and noted that groups of people also traveled the river in this manner.
==== Gliding lizards ==== There are two different mechanisms by which lizards glide through the air. Both mechanisms involve the patagia. In the active mechanism, skeletal supports and muscles run through the patagia of lizards. The skeletal supports and muscle erect the flight membrane and control the gliding using the patagia. Most of the lizards that exhibit this active gliding mechanism are agamine lizards such lizards in the genus Draco. For the passive mechanism of gliding in lizards, the patagia is unfurled by air pressure alone. The patagia of the passive mechanism differs from patagia of the active mechanism; there is the lack of skeleton support and musculature in patagia of the gliding lizards with the passive gliding mechanism. The passive mechanism of gliding is seen in smaller lizards such as the geckos of the genus Ptychozoon. For the passive mechanism of gliding, body movements are believed to control the descent of the gliding lizard. The surface area to body ratios of lizards with different gliding mechanisms are similar, but how the surface area is distributed is different. The difference in the distribution of surface area indicates the differences in the role of the patagia and accessory areas for the different flight mechanisms. Lizards with passive gliding mechanisms tend to have smaller patagia relative to lizards with active flight mechanisms. However, lizards with passive flight mechanism have, ore surface area located in accessory areas (i.e. webbed toes, tail) than lizards with the active gliding mechanism.
Sources: en.wikipedia.org
== Leukotrienes in asthma == Leukotrienes contribute to the pathophysiology of asthma, especially in patients with aspirin-exacerbated respiratory disease (AERD), and cause or potentiate the following symptoms:
=== 2006–2016: Big Love and final roles === In 2006, Chase secured the role of Rhonda Volmer in Big Love, a critically acclaimed drama series on HBO which centered on a polygamist family in Utah led by patriarch Bill Henrickson (Bill Paxton). Chase's character, Rhonda, was introduced as the teenage child bride of the compound's ruthless prophet, Roman Grant (Harry Dean Stanton). Chase remained a recurring and main presence on the series until its conclusion in 2011, earning praise for her chilling depiction of a young woman corrupted by religious extremism. Also in 2006, Chase voiced Lilo for the final time in Leroy & Stitch, the conclusion to the Lilo & Stitch television series. In 2008, she took on the voice role of Betsy in the PBS Kids educational animated series Betsy's Kindergarten Adventures. In 2009, Chase reprised her Donnie Darko role as Samantha in the sequel S. Darko. Set seven years after the events of the original film, the narrative follows an 18-year-old Samantha on a cross-country road trip to Los Angeles, where she becomes plagued by bizarre visions and time anomalies. Unlike its predecessor, S. Darko received overwhelmingly negative reviews from critics. Having been made without the approval of (nor input from) the original film's creator, Richard Kelly, the sequel shares minimal continuity with its predecessor. During the 2010s, Chase appeared primarily in independent thriller and horror films. She played a supporting role in the drama Yellow (2012) and starred in the independent thriller Killer Crush (2015).
== Gene expression == The CCND1 gene encodes the cyclin D1 protein. The human CCND1 gene is located on the long arm of chromosome 11 (band 11q13). It is 13,388 base pairs long, and translates into 295 amino acids. Cyclin D1 is expressed in all adult human tissues with the exception of cells derived from bone marrow stem cell lines (both lymphoid and myeloid).
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.